Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi
Open Access
- 1 January 2010
- journal article
- Published by Springer Science and Business Media LLC in Thyroid Research
- Vol. 3 (1), 9
- https://doi.org/10.1186/1756-6614-3-9
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Low vs. High Radioiodine Activity to Ablate the Thyroid after Thyroidectomy for Cancer: A Randomized StudyPLOS ONE, 2008
- [Optimization of 131I ablation in patients with differentiated thyroid carcinoma: comparison of early outcomes of treatment with 100 mCi versus 60 mCi].2006
- European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epitheliumActa Endocrinologica, 2006
- Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled StudyJournal of Clinical Endocrinology & Metabolism, 2006
- A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid CancerJournal of Clinical Endocrinology & Metabolism, 2004
- [Early evaluation of treatment effectiveness using 131I iodine radiotherapy in patients with differentiated thyroid cancer].2001
- An Overview of the Management of Papillary and Follicular Thyroid CarcinomaThyroid®, 1999
- Thyroid Remnant 131I Ablation for Papillary and Follicular Thyroid CarcinomaThyroid®, 1997
- Prospective randomized clinical trial to evaluate the optimal dose of131I for remnant ablation in patients with differentiated thyroid carcinomaCancer, 1996
- Low dose radioiodide thyroid ablation in postsurgical patients with thyroid cancerAmerican Journal Of Medicine, 1976